Omixon

Executive Summary

Omixon is a Hungarian molecular diagnostics company specializing in next-generation sequencing (NGS) solutions for human leukocyte antigen (HLA) typing, a critical step in transplant compatibility matching. Founded in 2010, the company offers integrated assay and software products, including its flagship Holotype HLA™ and the newer NanoTYPE™ long-read sequencing platform. By enabling high-resolution, cost-effective HLA typing, Omixon aims to improve transplant outcomes and streamline histocompatibility workflows. The company serves a niche but growing market driven by increasing transplant volumes and the shift toward NGS-based typing. While privately held with limited financial disclosures, Omixon's innovative long-read technology positions it well against competitors like Illumina and Thermo Fisher. Key challenges include adoption barriers in clinical labs and regulatory approvals for new markets.

Upcoming Catalysts (preview)

• Q3 2026CE-IVD marking for NanoTYPE long-read HLA typing kit80% success
• Q3 2026Strategic partnership with a major transplant center network60% success
• Q2 2026Publication of clinical validation study for Holotype HLA in high-resolution typing90% success